omega-n-methylarginine has been researched along with 9-(2-hydroxy-3-nonyl)adenine in 3 studies
| Studies (omega-n-methylarginine) | Trials (omega-n-methylarginine) | Recent Studies (post-2010) (omega-n-methylarginine) | Studies (9-(2-hydroxy-3-nonyl)adenine) | Trials (9-(2-hydroxy-3-nonyl)adenine) | Recent Studies (post-2010) (9-(2-hydroxy-3-nonyl)adenine) |
|---|---|---|---|---|---|
| 4,411 | 344 | 336 | 428 | 1 | 33 |
| 4,411 | 344 | 336 | 30 | 0 | 11 |
| Protein | Taxonomy | omega-n-methylarginine (IC50) | 9-(2-hydroxy-3-nonyl)adenine (IC50) |
|---|---|---|---|
| cGMP-dependent 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 2.145 | |
| High affinity cAMP-specific and IBMX-insensitive 3',5'-cyclic phosphodiesterase 8A | Homo sapiens (human) | 0.8 | |
| cGMP-specific 3',5'-cyclic phosphodiesterase | Homo sapiens (human) | 0.8 | |
| cAMP-specific 3',5'-cyclic phosphodiesterase 4D | Homo sapiens (human) | 0.8 | |
| cGMP-inhibited 3',5'-cyclic phosphodiesterase A | Homo sapiens (human) | 0.8 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Addicks, K; Andressen, C; Bloch, W; Feelisch, M; Fleischmann, BK; Hescheler, J; Ji, GJ | 1 |
| Alloatti, G; Bedendi, I; Biasin, C; Gallo, MP; Levi, RC; Malan, D | 1 |
| Axe, FU; Bembenek, SD; Butler, CR; Coles, F; Dunford, PJ; Edwards, JP; Fourie, AM; Grice, CA; Karlsson, L; Lundeen, K; Riley, JP; Savall, BM; Tays, KL; Wei, J; Williams, KN; Xue, X | 1 |
3 other study(ies) available for omega-n-methylarginine and 9-(2-hydroxy-3-nonyl)adenine
| Article | Year |
|---|---|
Regulation of the L-type Ca2+ channel during cardiomyogenesis: switch from NO to adenylyl cyclase-mediated inhibition.
Topics: Adenine; Adenylyl Cyclase Inhibitors; Animals; Calcium Channels; Electrophysiology; Enzyme Inhibitors; Heart; Ion Channel Gating; Mice; NG-Nitroarginine Methyl Ester; Nitric Oxide; Nitric Oxide Synthase; omega-N-Methylarginine; Stem Cells | 1999 |
Regulation of cardiac calcium current by NO and cGMP-modulating agents.
Topics: Adenine; Animals; Arginine; Biological Transport; Calcium Channels, L-Type; Carbachol; Cholinergic Agonists; Cyclic GMP; Cyclic N-Oxides; Enzyme Inhibitors; Exonucleases; Free Radical Scavengers; Guinea Pigs; Imidazoles; In Vitro Techniques; Myocardium; Nitric Oxide; omega-N-Methylarginine; Orchiectomy; Oxadiazoles; Quinoxalines; Receptors, Muscarinic | 2001 |
Identification of a potent, selective, and orally active leukotriene a4 hydrolase inhibitor with anti-inflammatory activity.
Topics: Administration, Oral; Animals; Anti-Inflammatory Agents; Catalysis; Dogs; Drug Evaluation, Preclinical; Enzyme Inhibitors; Epoxide Hydrolases; Humans; Magnetic Resonance Spectroscopy; Mice; Structure-Activity Relationship | 2008 |